Error in Figure
In the original publication, there is a mistake in Figure 11B as published [1]. The images of the colony formation assay are misplaced. The corrected Figure 11 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Figure 11. Sulfasalazine (SSZ) treatment reduced the tumorigenic properties of CRC cells and enhanced cisplatin (CDDP) efficacy. (A) SSZ enhanced cisplatin efficacy in both the DLD-1 and HCT116 cell lines. IC50 values are shown. Representative micrographs for the suppressive effects of SSZ on the ability of DLD-1 and HCT116 cells to form (B) colonies and migration, and (C) tumorspheres, as well as showing reduced ALDH activity (cancer stemness marker) in DLD-1 and HCT116 cells. (D) Western blot results show that SSZ and CDDP combined treatment significantly reduced the expression level of KRAS, MMP7, and CD44 on CRC cells compared to their vehicle-treated counterparts. β-actin served as the loading control. ** p [less than] 0.01, *** p [less than] 0.001. Numbers in red represent the relative expression level of the band intensity estimated using ImageJ software.
Reference
1. Leung, W.-H.; Shih, J.-W.; Chen, J.-S.; Mokgautsi, N.; Wei, P.-L.; Huang, Y.-J. Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines; 2022; 10, 377. [DOI: https://dx.doi.org/10.3390/biomedicines10020377] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35203586]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details





1 Division of Colon and Rectal Surgery, Department of Surgery, Mackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd., Taipei 10449, Taiwan;
2 Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan;
3 Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan;
4 Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 110, Taiwan;